journal article·2024-05-01Open access

Impact of 3-O-caffeoylquinic acid (chlorogenic acid) and Postn protein regulation on cardiomyocyte hypertrophy: Experimental insights and potential therapeutic implications

Naiwei Li, Zhou Yang, Fang Wang, Mustafa Sawsan Aloahd, Lui Nang

AIP Advances· Volume 14· Issue 5

Abstract

Background: Cardiac hypertrophy is characterized by an enlarged heart muscle, often due to increased workload or chronic heart diseases. Postn protein (periostin) plays a significant role in cardiac hypertrophy by influencing cardiomyocyte proliferation, inflammatory response, and fibrosis. The TGF-β and NF-κB pathways exacerbate inflammatory responses and structural changes in the heart during cardiac hypertrophy. Chlorogenic acid, found in plants, has antioxidant and anti-inflammatory properties, making it a potential candidate for inhibiting cardiac hypertrophy. Method: We used angiotensin II-induced H9c2 cardiomyocytes to construct a cell model of cardiac hypertrophy. Cells were categorized into control, model, shPostn, chlorogenic acid, and shPostn+chlorogenic acid groups. Various parameters, including cell surface area, activity, apoptosis rate, and expression levels of Postn, TGF-β/NF-κB pathway-related proteins, and mRNA, were evaluated. Results: Compared to the control group, the model group exhibited increased cell surface area and apoptosis rate, along with decreased cell activity. However, intervention with shPostn or chlorogenic acid led to significant reductions in cell surface area and apoptosis rate, coupled with increased cell viability. The shPostn+chlorogenic acid group showed further improvements. In addition, protein and mRNA expressions related to Postn, TGF-β/NF-κB pathways, and cardiac hypertrophy markers were upregulated in the model group but downregulated in the intervention groups, particularly the shPostn+chlorogenic acid group. Conclusion: Chlorogenic acid exerts its inhibitory effect on cardiac hypertrophy by modulating the TGF-β/NF-κB pathway through Postn protein. This study sheds light on potential therapeutic strategies for mitigating cardiac hypertrophy induced by angiotensin II and highlights chlorogenic acid as a promising candidate for further exploration in treating this condition.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Adipose Tissue and Metabolism · Mitochondrial Function and Pathology · Cardiac Ischemia and Reperfusion

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Fuzhou Medical College of Nanchang University 1 , Fuzhou, Jiangxi, China

Medical College, Hospital of Jilin University 2 , Changchun 130021, China

Department of Biology, Hospital of Jilin University 3 , Changchun 130021, China

College of Life Science, Maulana Azad College of Arts and Science 4 , Aurangabad, India and , Baghdad, Iraq

Department of Biology, Wasit University 4 , Aurangabad, India and , Baghdad, Iraq

References (26)

Show source-provided references
1. Targeting miR-30d reverses pathological cardiac hypertrophy10.1016/j.ebiom.2022.104108 ↗
2. Lupeol protects against cardiac hypertrophy via TLR4-PI3K-Akt-NF-κB pathways10.1038/s41401-021-00820-3 ↗
3. USP25 ameliorates pathological cardiac hypertrophy by stabilizing SERCA2a in cardiomyocytes10.1161/CIRCRESAHA.122.321849 ↗
4. CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure10.1084/jem.20200418 ↗
5. METTL14 is required for exercise-induced cardiac hypertrophy and protects against myocardial ischemia-reperfusion injury10.1038/s41467-022-34434-y ↗
6. RNF207 exacerbates pathological cardiac hypertrophy via post-translational modification of TAB110.1093/cvr/cvac039 ↗
7. Angiotensin II-induced signal transduction mechanisms for cardiac hypertrophy10.3390/cells11213336 ↗
8. ANGPTL8 is a negative regulator in pathological cardiac hypertrophy10.1038/s41419-022-05029-8 ↗
9. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure10.1038/s41569-022-00756-z ↗
10. S-nitrosylation of Hsp90 promotes cardiac hypertrophy in mice through GSK3β signaling10.1038/s41401-021-00828-9 ↗
11. METTL3 mediates Ang-II-induced cardiac hypertrophy through accelerating pri-miR-221/222 maturation in an m6A-dependent manner10.1186/s11658-022-00349-1 ↗
12. CDC-like kinase 4 deficiency contributes to pathological cardiac hypertrophy by modulating NEXN phosphorylation10.1038/s41467-022-31996-9 ↗
13. Limonin stabilises sirtuin 6 (SIRT6) by activating ubiquitin specific peptidase 10 (USP10) in cardiac hypertrophy10.1111/bph.15899 ↗
14. Eosinophils protect pressure overload- and β-adrenoreceptor agonist-induced cardiac hypertrophy10.1093/cvr/cvac060 ↗
15. Phillyrin attenuates norepinephrine-induced cardiac hypertrophy and inflammatory response by suppressing p38/ERK1/2 MAPK and AKT/NF-κB pathways10.1016/j.ejphar.2022.175022 ↗
16. Aloe-emodin ameliorated MI-induced cardiac remodeling in mice via inhibiting TGF-β/SMAD signaling via up-regulating SMAD710.1016/j.phymed.2023.154793 ↗
17. Phillyrin inhibits isoproterenol-induced cardiac hypertrophy via P38 and NF-κB pathways10.1177/1934578X221144581 ↗
18. Visfatin amplifies cardiac inflammation and aggravates cardiac injury via the NF-κB p65 signaling pathway in LPS-treated mice10.1155/2022/3306559 ↗
19. Tongxinluo-pretreated mesenchymal stem cells facilitate cardiac repair via exosomal transfer of miR-146a-5p targeting IRAK1/NF-κB p65 pathway10.1186/s13287-022-02969-y ↗
20. [Retracted] IL-33 attenuates cardiac remodeling following myocardial infarction via inhibition of the p38 MAPK and NF-κB pathways10.3892/mmr.2022.12868 ↗
21. Maternal ethanol exposure-induced cardiac fibrosis is associated with changes in TGF-β and SIRT1/FOXO3a signaling in male rat offspring: A three-month follow-up study10.1007/s12012-022-09761-7 ↗
22. Leonurine inhibits cardiomyocyte pyroptosis to attenuate cardiac fibrosis via the TGF-β/Smad2 signalling pathway10.1371/journal.pone.0275258 ↗
23. Sustained AT1R stimulation induces upregulation of growth factors in human cardiac fibroblasts via Gαq/TGF-β/ERK signaling that influences myocyte hypertrophy10.1016/j.ejphar.2022.175384 ↗
24. QiShenYiQi pill ameliorates cardiac fibrosis after pressure overload-induced cardiac hypertrophy by regulating FHL2 and the macrophage RP S19/TGF-β1 signaling pathway10.3389/fphar.2022.918335 ↗
25. Fibroblast GSK-3α promotes fibrosis via RAF-MEK-ERK pathway in the injured heart10.1161/CIRCRESAHA.122.321431 ↗
26. METTL3 boosts glycolysis and cardiac fibroblast proliferation by increasing AR methylation10.1016/j.ijbiomac.2022.11.042 ↗